Emcure Pharmaceuticals IPO Listing Today :Shark Tank judge Namita Thapar’s company Emcure Pharmaceuticals has got a strong listing in the stock market today. The company’s share was listed on BSE at a price of Rs 1325, while the upper price band in the IPO was Rs 1008. In this sense, investors have made a profit of 31 percent or Rs 317 per share on listing. This IPO was subscribed 68 times overall, while there was a craze about it in the grey market as well. Brokerage houses are positive on the company’s outlook. The question is whether to sell the shares after the listing gains or hold on.
After Modi became PM, these mutual fund schemes did wonders, returns up to 920%, industry grew 6 times
It was subscribed 68 times
Emcure Pharmaceuticals’ IPO was oversubscribed 68 times overall. 35 per cent of the IPO was reserved for retail investors and it was oversubscribed 7.30 times overall. 50 per cent of it was reserved for qualified institutional buyers (QIB) and it was oversubscribed 191.24 times. While 15 per cent was reserved for non-institutional investors (NII) and it was oversubscribed 49.27 times. The portion reserved for employees was oversubscribed 8.77 times.
Sensex @80K: Bullish momentum in the market, best 21 largecap and midcap stocks for portfolio
Company Outlook
According to brokerage house Geojit, given its strong research and development expertise in differentiated products, established domestic and international presence, strong focus on the healthcare market for women, improving profitability after the IPO and diversified product portfolio, its long-term outlook looks good. The brokerage had advised to subscribe to the IPO for mid to long term.
Company Strength
• Well positioned to take advantage of leverage in the domestic market
• Demonstrated capabilities of building brands
• Large, diversified and rapidly growing product portfolio in international markets
• Strong research and development capabilities drive a differentiated portfolio of products.
• Extensive and diversified manufacturing capacity
These stocks could not even beat the returns of FD in 5 years, got returns of only 1 to 4.50%, have you invested in any of them
The main strategy of the company
• Increasing market share in the domestic market.
• Continue to invest in research and development and manufacturing capabilities to enhance and develop a differentiated product portfolio.
• Deepening and expanding international presence with a focused go-to-market approach.
• Pursuing strategic acquisitions, partnerships and in-licensing arrangements.
13 to 16% return in a month, you can earn profit up to Rs 32 thousand by investing Rs 2 lakh
Risk with the company
A significant portion of domestic revenues, 57 per cent in FY14, comes from acute therapies, which are subject to strong competition.
(Disclaimer: Investing or selling stocks is advised by the brokerage house. These are not the personal views of Financial Express. There are risks in the market, so take expert advice before investing.)